The treatment of trichomonal vaginitis using single dose tinidazole (Fasigyn-Pfizer).
A total of twenty eight patients living in a around the City of Lusaka, Zambia were subjected to a drug trial to determine the effect of a single oral dose of Tinidazole (Fasigyn Pfizer) in the treatment of Trichomonal Vaginitis. All the twenty eight patients were proven cases of Trichomonal Vaginitis from microscopy of cervical smears. Two grammes of Fasigyn were used as a single oral dose with yeast as Placebo. Twenty patients were originally treated with Fasigyn and eight received yeast. However two patients in the Fasigyn group absconded, but one later reported satisfactory results. The husbands of two others were untreated. Four patients had other vaginal infections. A microscopic cure rate of 100% and a corrected clinical cure rate of 93.3% was obtained using fasigyn. The side effects were minimal and the patients themselves regarded them as mild.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009593:Nitroimidazoles / Q000627:therapeutic use*; D012008:Recurrence; D014011:Tinidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D014247:Trichomonas Vaginitis / Q000175:diagnosis / Q000188:drug therapy*; D014626:Vaginal Smears
D009593:Nitroimidazoles; D014011:Tinidazole